Abstract:Antibody–drug conjugates (ADCs) are an innovative family of agents assembled through linking cytotoxic drugs (payloads) covalently to monoclonal antibodies (mAbs) to be delivered to tumor tissue that express their particular antigen, with the theoretical advantage of an augmented therapeutic ratio. As of June 2023, eleven ADCs have been approved by the Food and Drug Administration (FDA) and are on the market. These drugs have been added to the therapeutic armamentarium of acute myeloblastic and lymphoblastic leukemias, various types of lymphoma, breast, gastric or gastroesophageal junction, lung, urothelial, cervical, and ovarian cancers. They have proven to deliver more potent and effective anti-tumor activities than standard practice in a wide variety of indications. In addition to targeting antigen-expressing tumor cells, bystander effects have been engineered to extend cytotoxic killing to low-antigen-expressing or negative tumor cells in the heterogenous tumor milieu. Inevitably, myelosuppression is a common side effect with most of the ADCs due to the effects of the cytotoxic payload. Also, other unique side effects are specific to the tissue antigen that is targeted for, such as the cardiac toxicity with Her-2 targeting ADCs, and the hemorrhagic side effects with the tissue factor (TF) targeting Tisotumab vedotin. Further exciting developments are centered in the strategies to improve the tolerability and efficacy of the ADCs to improve the therapeutic window; as well as the development of novel payloads including (1) peptide–drug conjugates (PDCs), with the peptide replacing the monoclonal antibody, rendering greater tumor penetration; (2) immune-stimulating antibody conjugates (ISACs), which upon conjugation of the antigen, cause an influx of pro-inflammatory cytokines to activate dendritic cells and harness an anti-tumor T-cell response; and (3) the use of radioactive isotopes as a payload to enhance cytotoxic activity.

Antibody-drug conjugates in gynecologic malignancies

Antibody-Drug Conjugates in Gynecologic Cancers

The target invites a foe: antibody-drug conjugates in gynecologic oncology

Antibody-Drug Conjugates in Gynecologic Cancer

Advances in antibody-drug conjugates for gynecologic malignancies

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors

[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]

Research progress of antibody–drug conjugates in gynecologic cancer

Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

A Review of Current and Future Antibody Drug Conjugates in Breast Cancer

Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody-drug conjugates in solid tumors: a look into novel targets

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

Antibody-drug conjugates—an emerging class of cancer treatment

Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions

Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads